Establishment of Paclitaxel-Resistant Cell Line and the Underlying Mechanism on Drug Resistance

This publication has 18 references indexed in Scilit:

• Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells
  Oncology Letters, 2010
• Achievements and unmet needs in the management of advanced ovarian cancer
  Gynecologic Oncology, 2010
• Suppression of NF-κB Activation by Entamoeba histolytica in Intestinal Epithelial Cells Is Mediated by Heat Shock Protein 27
  Journal of Biological Chemistry, 2006
• Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer
  Clinical Cancer Research, 2006
• Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line
  International Journal of Gynecological Cancer, 2006
• Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study
  Gynecologic Oncology, 2006
• Myocardial Ischemia Activates the JAK–STAT Pathway Through Angiotensin II Signaling in in vivo Myocardium of Rats
  Journal of Molecular and Cellular Cardiology, 2001
• Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
  Journal of Clinical Investigation, 1997
• Combination paclitaxel (TaxolR)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer
  International Journal of Gynecological Cancer, 1997
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996